Literature DB >> 14730266

Antigenic and genetic variation in human respiratory syncytial virus.

Gail W Wertz1, Robin M Moudy.   

Abstract

BACKGROUND: Human respiratory syncytial virus (HRSV) is a leading cause of serious pediatric respiratory disease worldwide. Natural infection provides only partial protection as repeat infections occur throughout life. A brief review of the extent of antigenic and genetic variation observed in HRSV clinical isolates is presented. METHODS AND
RESULTS: Recent experimental research is reviewed, describing key factors that may explain the ability of HRSV to cause multiple infections in the same individual even in the presence of an existing immune response. It is well-appreciated that variability of the G protein, both between and within antigenic subgroups A and B, is partially responsible for repeat HRSV infections. A high level of nucleotide change resulting in amino acid change provides strong evidence for selective pressure for change in G sequences, thus new HRSV variants. Although little variation in gene-coding sequences is observed in the F protein (the second major protective antigen), new evidence of genetic variation has identified alteration of gene expression levels by selection of changes in the gene end termination signal that precedes the gene encoding the F protein. Due to obligatory sequential transcription, these changes affect downstream gene expression levels. These data suggest that modulation of F protein levels may provide a selective advantage in the presence of a preexisting immune response.
CONCLUSIONS: Experimental data in HRSV demonstrate that variation exists not only in gene-coding sequences but also in the signals that control gene expression. Thus alteration in the expression of key proteins provides a second type of antigenic "variation." A better understanding of these differences is critical to the development of an effective vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730266     DOI: 10.1097/01.inf.0000108189.87181.7c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

Review 1.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes.

Authors:  Amit Agrawal; Ralph A Tripp; Larry J Anderson; Shuming Nie
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Replacement of previously circulating respiratory syncytial virus subtype B strains with the BA genotype in South Africa.

Authors:  Stephanie van Niekerk; Marietjie Venter
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

4.  Human pathogenic RNA viruses establish noncompeting lineages by occupying independent niches.

Authors:  Pascal Mutz; Nash D Rochman; Yuri I Wolf; Guilhem Faure; Feng Zhang; Eugene V Koonin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-31       Impact factor: 12.779

5.  Features of the Human Antibody Response against the Respiratory Syncytial Virus Surface Glycoprotein G.

Authors:  Kristina Borochova; Katarzyna Niespodziana; Katarina Stenberg Hammar; Marianne van Hage; Gunilla Hedlin; Cilla Söderhäll; Margarete Focke-Tejkl; Rudolf Valenta
Journal:  Vaccines (Basel)       Date:  2020-06-25

6.  Virologic study of acute lower respiratory tract infections in children admitted to the paediatric department of Blida University Hospital, Algeria.

Authors:  F Derrar; K Izri; C Kaddache; R Boukari; D Hannoun
Journal:  New Microbes New Infect       Date:  2019-03-27

7.  Circulation of HRSV in Belgium: from multiple genotype circulation to prolonged circulation of predominant genotypes.

Authors:  Lieselot Houspie; Philippe Lemey; Els Keyaerts; Eva Reijmen; Valentijn Vergote; Anne Vankeerberghen; Freya Vaeyens; Hans De Beenhouwer; Marc Van Ranst
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.